“Let’s Find the Reason for the U.S. Clinical Failure”… Kolon TissueGene CEOs Give up Their Vacations

조선일보

Lean Right

Factuality

Ownership

This summer, executives at pharmaceutical and biotech companies are giving up their vacations and returning to work. In the case of Kolon TissueGene, the atmosphere is one of focusing on work to make up for the failure of its Phase 3 clinical trial for an osteoarthritis treatment. As the economic downturn and shrinking investment continue for the long term, there are also instances where executives are prioritizing on-site operations over vacati…